N Wang
In vivo efficiency of praziquantel treatment of single-sex Schistosoma three months old in mice
Wang, N; Peng, HQ; Gao, CZ; Cheng, YH; Sun, MT; Qu, GL; Webster, JP; Lu, DB
Authors
HQ Peng
CZ Gao
YH Cheng
MT Sun
GL Qu
JP Webster
DB Lu
Abstract
Schistosomiasis is a major neglected tropical disease mainly caused by Schistosoma haematobium, S. japonicum and S. mansoni, and results in the greatest disease burden. Mass drug administration (MDA) with praziquantel (PZQ), a single drug only available for the disease, has played a vital role in schistosomiasis control. Therefore, any possibility of selection of the parasites for PZQ resistance or low sensitivity may hamper the 2030's target of global disease elimination. We had experimentally demonstrated the long-term survival and reproductive potential of single-sex (of either sex) S. japonicum infections in definitive hosts mice. What has not yet been adequately addressed is whether the long live single-sex schistosomes remain sensitive to PZQ, and what reproduction potential for those schistosomes surviving treatment may have. We therefore performed experimental mice studies to explore the treatment effectiveness of PZQ (at total doses of 200 or 400 mg/kg, corresponding to the sub-standard or standard treatment doses in humans) for single-sex S. japonicum aged three months old. The results showed that no treatment efficiency was observed on female schistosomes, whereas on male schistosomes only at PZQ 400 mg/kg a significant higher efficiency in reducing worm burdens was observed. Moreover, either schistosome males or females surviving PZQ treatment remained their reproduction potential as normal. The results indicate that long (i.e., three months) live single-sex S. japonicum can easily survive the current treatment strategy, and moreover, any schistosomes, if with PZQ resistance or low sensitivity, could be easily transmitted in nature. Therefore, in order to realize the target for the national and the global schistosomiasis elimination, there is undoubtedly a great need for refining PZQ administration and dosage, looking for alternative therapies, and/or developing vaccines against schistosome.
Citation
Wang, N., Peng, H., Gao, C., Cheng, Y., Sun, M., Qu, G., Webster, J., & Lu, D. (2022). In vivo efficiency of praziquantel treatment of single-sex Schistosoma three months old in mice. International Journal for Parasitology: Drugs and Drug Resistance, 20, 129-134. https://doi.org/10.1016/j.ijpddr.2022.11.002
Journal Article Type | Article |
---|---|
Acceptance Date | Nov 8, 2022 |
Online Publication Date | Nov 12, 2022 |
Publication Date | 2022 |
Deposit Date | Aug 16, 2023 |
Publicly Available Date | Aug 16, 2023 |
Journal | International Journal for Parasitology: Drugs and Drug Resistance |
Print ISSN | 2211-3207 |
Electronic ISSN | 2211-3207 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 20 |
Pages | 129-134 |
DOI | https://doi.org/10.1016/j.ijpddr.2022.11.002 |
Keywords | S; japonicum; Single -sex infection; Praziquantel; Treatment efficiency; JAPONICUM; MANSONI; RESISTANCE; CHINA; ANHUI |
Files
In Vivo Efficiency Of Praziquantel Treatment Of Single-sex Schistosoma Three Months Old In Mice
(1 Mb)
PDF
Licence
http://creativecommons.org/licenses/by-nc-nd/4.0/
Publisher Licence URL
http://creativecommons.org/licenses/by-nc-nd/4.0/
Version
VoR
You might also like
Evolution of tetraspanin antigens in the zoonotic Asian blood fluke Schistosoma japonicum
(2023)
Journal Article
Is the incidence of congenital toxoplasmosis declining?
(2022)
Journal Article